The JI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     
 

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Coccia, M. A.
Right arrow Articles by Brams, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Coccia, M. A.
Right arrow Articles by Brams, P.
The Journal of Immunology, 1998, 161: 5772-5780.
Copyright © 1998 by The American Association of Immunologists

High Titer, Prostate Specific Antigen-Specific Human IgG Production by hu-PBL-SCID Mice Immunized with Antigen-Mouse IgG2a Complex-Pulsed Autologous Dendritic Cells1

Marco A. Coccia2 and Peter Brams

Human Immunology Group, IDEC Pharmaceuticals, Inc., San Diego, CA 92121


   Abstract
Top
 Abstract
Introduction
 Materials and Methods
 Results
 Discussion
 References
 
We report here that immunization of human PBMC reconstituted SCID mice (hu-PBL-SCID mice) with in vitro cultured autologous dendritic cells (DC) pulsed with prostate specific antigen (PSA) complexed to a PSA-specific mouse IgG2a (PSA-IgG2a) consistently and reproducibly stimulates PSA-specific human IgG production. On day 0, female PBMC were used to reconstitute SCID mice and to generate DC in vitro. DC cultures were pulsed with PSA or PSA-IgG2a on day 6. The previously reconstituted hu-PBL-SCID mice were immunized with either PSA-pulsed DC and PSA, PSA-IgG2a-pulsed DC and PSA-IgG2a, or additional PBMC and PSA-IgG2a on day 7. Mice immunized with PSA-IgG2a-pulsed DC had, on the average, up to 31.5 times greater PSA-specific IgG serum concentrations than control mice. Competition ELISA confirmed the PSA specificity of serum IgG. Immunoblot analysis suggested that sera IgG preferentially recognized conformational epitopes on PSA. Therefore, our results represent a major step toward cloning human tumor-associated Ag-specific human mAbs from hu-PBL-SCID mice. In addition, flow cytometry showed that PSA-pulsed DC express significantly more B7.1, B7.2, CD40, and MHC class II surface molecules than mock-treated DC, but PSA-IgG2a-pulsed DC only had significantly enhanced B7.2 surface expression. Interestingly, PSA-specific IgG responses were reproducibly stimulated by DC expressing more B7.2, a molecule associated with Th2-type immune deviation, but not by those expressing more B7.1 and CD40, molecules associated with Th1-type immune deviation. Thus, our results show that stimulation with either Ag or Ag complexed to mAb yields DC with different phenotypes and APC effector functions.


   Introduction
Top
 Abstract
 Introduction
Materials and Methods
 Results
 Discussion
 References
 
Severe combined immune deficiency mice are deficient in mature lymphocytes, Ig production, and lymphocyte-mediated immune responses due to defective Ig and TCR gene rearrangement (1). SCID mice reconstituted with normal human splenocytes (hu-SPL-SCID mice)3 or PBL (hu-PBL-SCID mice) can be effective models of T cell-mediated, recall Ag-directed Ig production by human B cells (2, 3, 4, 5). However, stimulation of weakly immunogenic neo-Ag, self-Ag, or tumor-associated Ag (TAA)-specific IgG production in hu-PBL-SCID mice reconstituted with normal donor PBMC and immunized with target Ag on adjuvant is difficult. We recently showed that hu-SPL-SCID mice immunized with horse ferritin on adjuvant could be stimulated to produce detectable levels of ferritin-specific IgG (2). Similarly, little or no neo-Ag-specific IgG production was stimulated in hu-PBL-SCID mice immunized with Ag complexed to highly immunogenic peptides (e.g., tetanus toxoid) on adjuvant (6). Only one case of self-Ag (CD2)-directed IgG production has been reported in hu-SCID mice. These mice were immunized with genetically modified CD2 protein (7). In addition, human tumor-specific IgG responses have only been generated in hu-SCID mice that were reconstituted with tumor-infiltrating lymphocytes present in coengrafted human tumor biopsy tissue (8).

Dendritic cells (DC) are professional APC that initiate an immune response (9, 10). Recently, several methods have been developed to generate human DC from PBMC-derived progenitor cells in vitro. These different culture methods yield DC subtypes with heterogeneous morphology, phenotype, and function. However, all these DC subtypes have been shown to be potent stimulators of naive Ag-specific T cells (11, 12, 13). This is due in large part to the fact that DC express class I and II MHC and costimulatory cell surface molecules B7.1 and B7.2 (14, 15). In addition, human DC pulsed with weakly immunogenic TAA are capable of stimulating TAA-specific CTL proliferation and cytotoxicity in vitro and in vivo, thus illustrating both their potency as APC and their potential utility as tumor-specific vaccines (16, 17, 18, 19).

DC derived from PBMC and cultured with GM-CSF and IL-4 express both the high affinity IgG receptor Fc{gamma}RI (CD64) and the low affinity IgG receptor Fc{gamma}RII (CD32) at varying levels (11, 20). Both CD64 and CD32 have been shown to mediate Ag uptake by DC (20, 21). Targeting Ag to Fc{gamma}R on human monocytes and DC via Ag-IgG complexes can reduce the quantity of Ag required for Ag-specific T cell activation (i.e., enhance the immunogenicity of an Ag) as much as 1000-fold (22, 23). It has been previously established that the Fc region of mouse IgG2a binds human CD64 with greater affinity than any other subtype of mouse Ig (24). Mouse IgG2a also binds human CD32 (25). Therefore, we investigated whether Ag can be targeted to Fc{gamma}R on in vitro cultured human DC by pulsing with Ag complexed to an Ag-specific mouse IgG2a.

We report here an immunization protocol that consistently and reproducibly stimulates hu-PBL-SCID mice to produce human IgG specific for the human TAA, prostate specific antigen (PSA). We show that immunizing hu-PBL-SCID mice with autologous DC pulsed with PSA complexed to a mouse IgG2a specific for human PSA (PSA-IgG2a) stimulates high titer, PSA-specific IgG production. In contrast, immunizing hu-PBL-SCID mice with PSA on alum, PSA-pulsed autologous DC, or additional PBMC and PSA-IgG2a stimulates sporadic, low level, or no PSA-specific IgG production. Contrary to expectations, our results also show that B7.1, B7.2, CD40, and MHC class II surface expression is significantly enhanced on soluble Ag-pulsed DC, but only B7.2 expression is significantly enhanced on PSA-IgG2a-pulsed DC. Interestingly, high titer, TAA-specific IgG production was specifically stimulated by DC with enhanced B7.2 expression, an immunoregulatory surface molecule associated with enhanced Th2-type immune deviation (26, 27, 28).


   Materials and Methods
Top
 Abstract
 Introduction
 Materials and Methods
Results
 Discussion
 References
 
DC generation in serum-free cultures

Blood donors were selected based on health, sex, and age (normal healthy female donors between 18–40 yr old). PBMC were obtained by leukopheresis or by venepuncture into heparin-coated tubes. RBC were removed from residual PBMC by hypotonic lysis in 0.13 M NH4Cl before cryopreservation in liquid N2. DC were grown essentially as described by Romani et al., except that Iscove’s complete medium (Iscove’s modified Dulbecco’s medium (Irvine Scientific, Santa Ana, CA) plus sodium pyruvate, minimal essential amino acids, L-glutamine (Sigma, St. Louis, MO), and gentamicin (Life Technologies, Grand Island, NY)) was supplemented with 2% Nutridoma HU (Boehringer Mannheim, Indianapolis, IN) instead of 10% FBS (11). This serum-free medium (IN2) contained <100 µg/ml (final concentration) of mostly human serum proteins. In addition, this medium contained no cytokines, Ig, complement, or other nonspecific mitogens or immunogens heterogeneously present in FBS and human serum. Freshly isolated and thawed PBMC were purified by Histopaque (Sigma) gradient separation, washed, and plated at 5 x 106 cells/ml in IN2 at 37°C for 2 h. Nonadherent cells were gently removed with the medium, additional 37°C IN2 was added, and the cells were incubated at 37°C for 5 additional min. Nonadherent cells were again gently removed, and the residual cells were cultured in IN2 supplemented with 500 U/ml IL-4 and 800 U/ml GM-CSF (Genzyme, Cambridge, MA). Cultures were fed with additional cytokines on day 3. Mouse monoclonal IgG2a specific for PSA (clone 10-P20; Fitzgerald Industries International, Concord, MA) was complexed with >99% pure PSA (Fitzgerald Industries International) at equimolar ratios and dialyzed against 1x HBSS at 4°C overnight (PSA-IgG2a). The DC-enriched cultures were pulsed with 25 µg/ml (final concentration) PSA, PSA-IgG2a in 500 µl of IN2, or an equivalent volume of IN2 on day 6. Unlike macrophages, by day 7 DC are no longer fully adherent cells. Loosely adherent and nonadherent cells were harvested on day 7.

Flow cytometric analysis

The following FITC and phycoerythrin (PE)-labeled mAbs were used: anti-HLA-DR, -DP, and -DQ (MHC class II); anti-CD1a, -CD3, -CD11c, -CD16, and -CD32w (Fc{gamma}RII); anti-CD33, -CD40, -CD45RO, and -CD64 (Fc{gamma}RI); anti-CD86 (B7.2) and FITC-labeled isotype controls (PharMingen, San Diego, CA); anti-CD4, -CD14, and -CD80 (B7.1) and PE-labeled isotype control (Becton Dickinson, San Jose, CA); anti-ABC (MHC class I; Harlan Bioproducts for Science, Indianapolis, IN); and goat anti-mouse Ig F(ab')2 (human absorbed) and goat F(ab')2 FITC-labeled isotype control (Southern Biotechnology Associates, Birmingham, AL).

To characterize the phenotype of serum-free cultured DC, cultures were grown as described above. The cultures were harvested on day 7, washed, and then resuspended in 4°C FACS buffer (1% BSA, 1x PBS, 0.1% sodium azide, and 40 µg/ml human IgG) at 1 x 106 cells/ml. The cells were aliquoted and stained for 45 min with FITC and PE-labeled Ab diluted to the manufacturers’ recommended concentrations. The cells were washed twice in FACS buffer, and data were acquired on a FACScan (Becton Dickinson). Data were analyzed using LYSIS I (Becton Dickinson) or Fcap List (Soft Flow Hungary, Pecs, Hungary) software. Analysis was performed on large, CD33+ DC cells gated by forward and side scatter.

To detect PSA-IgG2a binding to PSA-IgG2a-pulsed DC, cultures were grown from thawed donor 3 PBMC in six-well plates, pulsed with 25 µg/ml PSA-IgG2a or PSA or mock treated on day 6, and harvested on day 7. The day 7 DC were labeled with goat anti-mouse Ig F(ab')2 (human absorbed) and goat F(ab')2 FITC-labeled isotype control, washed, and analyzed as described above.

In experiments comparing the expression of immunoregulatory surface molecule on Ag-pulsed and naive DC, cultures were grown from three donors as described above, except these cultures were grown in three triplicate sets and in six-well plates. On day 6, one set of the three triplicate cultures generated from donors 1, 2, and 3 was pulsed with either 25 µg/ml PSA or 25 µg/ml PSA-IgG2a or was mock treated. DC were harvested on day 7, and the triplicate cultures were pooled before analysis. The cultures were harvested on day 7, Ab labeled, and analyzed individually, as described above. Specific reactivity data, shown as the {Delta}mean fluorescence intensity (MFI), were calculated as follows: MFI of FITC- or PE-labeled specific mAb - MFI of isotype- and fluorochrome-matched mAb control. Student’s paired t test was used to determine the statistical differences between Ag-stimulated and mock-treated naive DC. A value of p < 0.05 was considered statistically significant.

SCID mouse engraftment and immunization

PBMC were obtained from healthy random female donors by leukopheresis. RBC were removed by hypotonic lysis, as described above. Residual PBMC were frozen and stored as described above. Four- to six-week-old male Fox Chase ICR SCID mice (Taconic, Germantown, NY) were kept in ventilated microisolator cages and maintained according to National Institute of Health guidelines described in the Guide for Care and Use of Laboratory Animals. All engraftments and immunizations were performed i.p.

All mice were reconstituted with 1 x 108 PBMC on day 0 and immunized as shown in Fig. 1Go, with the specific exceptions noted in Results. Human Ig serum concentrations were determined by ELISA as described below. Student’s paired t test was used to determine the statistical differences between the average IgG serum concentration of group A or B mice and the average IgG serum concentration of group C mice. Similarly, Student’s paired t test was used to determine the statistical differences between the average IgG serum concentration of group D or E and the average IgG serum concentration of group F. A value of p < 0.05 was considered statistically significant. Group G mice with IgG serum concentrations less than 10 µg/ml by day 21 were considered improperly reconstituted and were removed from analysis.



View larger version (11K):
[in this window]
[in a new window]
  		FIGURE 1. Immunization protocol. The hu-PBL-SCID mice were immunized as shown, with minor exceptions noted in Materials and Methods and Results.

 
Serum Ig quantitative ELISA

Human Ig serum concentrations were assayed by quantitative ELISAs. ELISAs were performed in 96-well Immulon 2 U-bottom ELISA plates (Dynatech, Chantilly, VA). Human IgG and IgM ELISA plates were coated with 2 µg/ml polyclonal goat anti-human IgG or goat anti-human IgM (Southern Biotechnology Associates) in 50 mM bicarbonate buffer (pH 9.3) overnight. PSA-specific IgG plates were coated with >99% pure PSA at 4 µg/ml in bicarbonate buffer. PSA-specific IgG was quantitated using a mouse monoclonal IgG1 specific for PSA (clone ERPR8, ICN, Costa Mesa, CA) as a standard. Incubations were performed at room temperature in serially diluted duplicate wells. Binding of Ig was detected by horseradish peroxidase (HRP)-conjugated polyclonal goat anti-human IgM-HRP, polyclonal goat anti-human IgG-HRP, or polyclonal goat anti-mouse IgG-HRP secondary Ab (Southern Biotechnology Associates) followed by enzymatic development of o-phenylenediamine dihydrochloride (OPD; Sigma) substrate. Reactions were quenched with 4 N HCl, and the plates were read on an ELISA plate reader at OD490. The concentration of human Ig in hu-PBL-SCID serum was quantitated by comparison of OD490 values with serially diluted human Ig (Zymed, South San Francisco, CA) standard curves. Data for all ELISAs were acquired on a Thermomax plate reader (Molecular Devices, Sunnyvale, CA) and analyzed using SOFTmax 2.35 software (Molecular Devices).

Competition ELISA

Pooled sera from four group C mice were diluted 1/15 (113 µg/ml total IgG final concentration) or 1/20 (85 µg/ml total IgG final concentration) into triplicate wells containing serially diluted concentrations of PSA. Background binding was assayed using control human IgG (Zymed) diluted into triplicate wells (85 µg/ml final concentration) containing serially diluted concentrations of PSA. Soluble PSA inhibition of PSA-specific binding by group C serum IgG and background human IgG binding were detected using polyclonal goat anti-human IgG-HRP and OPD substrate, as described above.

Immunoblot analysis

Prestained m.w. standards and 2.5-µg PSA samples were boiled in 1x nonreducing Laemmli sample buffer for 5 min and then separated by SDS-PAGE using 4–20% gradient gels (NOVEX, San Diego, CA). Two replica gels were simultaneously transferred onto a single nitrocellulose membrane at 25 V for 2 h in transfer buffer (10 mM Tris-glycine (pH 8.3), 19% methanol, and 0.01% SDS). The blot was blocked in 5% goat serum, 1x PBS, 0.05% Tween-20 (GS-PBST) for 1 h at room temperature and washed briefly in PBST, and the two replica blots were separated. One blot was stained with pooled sera from four group C mice diluted 1/100 (0.92 µg/ml PSA-specific IgG) in GS-PBST for 2 h at room temperature. The other identical blot was incubated in GS-PBST with an equivalent amount (17 µg/ml) of control human IgG. Both blots were washed for 2 h in many changes of PBST. The blots were then incubated for 1 h at room temperature with HRP-conjugated goat anti-human IgG diluted 1/20,000 in GS-PBST followed by overnight washing in PBST. HRP binding was detected by incubation in SuperSignal ULTRA chemiluminescent substrate (Pierce, Rockford, IL) for 5 min and exposure to x-ray film for 30 s.

IgG4-specific ELISA

ELISAs were performed in 96-well Immulon 2 U-bottom ELISA plates (Dynatech Laboratories). Equal volumes of day 25 sera from the four best responding mice in groups A–C and day 28 sera from all four mice in groups D–F were pooled before analysis. Human IgG4 ELISA plates were coated with 1 µg/ml monoclonal mouse anti-human IgG4 (clone G17-4; PharMingen) in 50 mM bicarbonate buffer (pH 9.3) overnight. Incubations were performed at room temperature in serially diluted duplicate (groups A–C) or triplicate (groups D–F) wells. Binding of IgG4 was detected by mouse monoclonal anti-human IgG-HRP (clone G18-145; PharMingen) followed by enzymatic development of OPD substrate. Reactions were quenched with 4 N HCl, and the plates were read on a ELISA plate reader at OD490. The concentrations of human IgG4 in pooled hu-PBL-SCID sera were quantitated by comparison of OD490 values with serially diluted human myeloma generated IgG4 (The Binding Site, San Diego, CA) standard curves, respectively.


   Results
Top
 Abstract
 Introduction
 Materials and Methods
 Results
Discussion
 References
 
Serum-free cultured DC

Human DC were generated from PBMC using low protein, serum-free medium (IN2) supplemented with GM-CSF and IL-4 as described in Materials and Methods. The developmental characteristics of cultures generated in IN2 were similar to what was described by Romani et al. and others for DC generation in medium containing serum (11, 12, 13). Briefly, the cells selected for adherence to plastic began aggregating into large clusters on day 2. These clusters increased in size and became decreasingly adherent until day 7, when most of the cells with dendritic morphology were loosely adherent or nonadherent to the culture flask. Cultures generated from 10 individual PBMC donors were between 50–85% (typically 75%) large MHC class I+/MHC class II+/CD11chigh/CD32+/CD33+/CD40+/CD45RO+/B7.1+/B7.2+ cells with dendritic morphology (Fig. 2Go). The remaining cells were mostly T cells and some B cells. DC generated from different donors were heterogeneous for CD1a, CD4, CD14, and CD64 expression (results not shown).



View larger version (35K):
[in this window]
[in a new window]
  		FIGURE 2. Phenotype of PBMC-derived DC cultured in serum-free medium. DC were grown from donor 1 PBMC in IN2, harvested on day 7, and subjected to FACS analysis as described in Materials and Methods. Dashed lines show matched isotype-negative control background binding. Solid lines show specific Ab binding. These results are representative of DC cultures generated from 10 individual PBMC donors. All donors generated cultures that were between 50–80% CD11chigh/CD32+/CD33+/CD40+/CD45RO+/class II+/B7.1+/B7.2+ DC. DC cultures generated from donor 1 PBMC were 65% large, MHC class II+/CD1alow/CD14low/CD32+/CD33+/CD40+/CD64+/B7.1+/B7.2+ cells with dendritic morphology.

 
To certify that PSA-IgG2a bound to human DC, cultures were grown from donor 3 PBMC, pulsed with either PSA or PSA-IgG2a or mock treated on day 6, and harvested on day 7. DC were stained with anti-CD64 and FITC-labeled, human Ig-absorbed goat F(ab')2 specific for mouse Ig, as described in Materials and Methods. The data showed that donor 3 DC were heterogeneous for CD64 expression and that PSA-IgG2a-pulsed DC had detectable quantities of mouse Ig (PSA-IgG2a) on their surface (Fig. 3GoB).



View larger version (23K):
[in this window]
[in a new window]
  		FIGURE 3. Flow cytometric analysis of PSA-IgG2a binding to DC cell surface. Donor 3 DC cultures were Ag pulsed, harvested, labeled, and analyzed by flow cytometry, as described in Materials and Methods. A, FITC-labeled anti-CD64 (solid lines) staining compared with FITC-labeled IgG2b isotype control (dashed lines). The data show that many donor 3 DC are CD64+ B, Goat F(ab')2 anti-mouse Ig (human Ig absorbed) binding to PSA-IgG2a pulsed DC (solid line) compared with 1) FITC-labeled goat F(ab')2 isotype control (dashed line), 2) PSA-pulsed DC (dashed and dotted line), and 3) mock-treated DC (dotted line). The data show that PSA-IgG2a was present on the cell surface of PSA-IgG2a-pulsed DC and that FITC-labeled goat F(ab')2 anti-mouse Ig did not cross-react with human IgG that may have also been present on PSA-IgG2a-pulsed and mock-treated DC.

 
PSA-specific IgG production in hu-PBL-SCID mice

Similar to what has been previously reported for other weakly immunogenic neo-Ag, our preliminary experiments confirmed that immunization of hu-PBL-SCID mice with PSA on adjuvant did not stimulate detectable PSA-specific human IgG responses (data not shown) (1, 29). This suggested that successful generation of PSA-specific IgG responses required an immunization protocol that enhanced the immunogenicity of PSA. We therefore analyzed whether PSA-specific IgG responses could be generated by 1) targeting PSA to Fc{gamma}R on endogenous APC by immunization of hu-SCID mice with PSA-IgG2a, 2) targeting PSA directly to autologous DC by pulsing in vitro cultured DC with soluble PSA, or 3) combining these immunogenicity enhancing strategies. To test these possibilities, three groups of hu-PBL-SCID mice (eight mice per group) were engrafted with 1 x 108 donor 1 PBMC on day 0 (Fig. 1Go). Autologous DC cultures were simultaneously initiated on day 0, pulsed with either PSA or PSA-IgG2a on day 6, and harvested on day 7 as described in Materials and Methods. Group A mice were immunized with 7 x 106 thawed autologous PBMC on day 7; 25 µg of PSA-IgG2a on days 0, 7 and 14; and 25 µg of PSA on day 21. Group B mice were immunized with 7 x 106 PSA-pulsed DC cultures on day 7 and 25 µg of PSA weekly starting on day 0. Group C mice were immunized with 7.5 x 106 PSA-IgG2a-pulsed DC cultures on day 7; 25 µg of PSA-IgG2a on days 0, 7, and 14; and 25 µg PSA on day 21. Serum was collected on days 14, 25, and 28. DC cultures generated from donor 1 were 65% CD1alow/CD14low/CD32+/CD64low DC (Fig. 2Go). Mice in all three groups had similar total and PSA-specific IgM serum concentrations on day 14 (Fig. 4Go, A and B). In contrast, on day 28 PSA-specific IgG concentrations in group A, B, and C sera averaged 2.3, 2.2, and 70.8 µg/ml, respectively (Fig. 4GoC). Therefore, on day 28 the average PSA-specific IgG concentration in group C serum was approximately 31.5-fold greater than the average PSA-specific IgG concentrations in control mice. On day 28, the average IgG concentrations in group A, B, and C sera were 0.3, 0.6, and 1.5 mg/ml, respectively (Fig. 4GoD). Therefore, the percentage of PSA-specific IgG in group A, B, and C sera averaged 0.5, 0.6, and 4.2%, respectively (Fig. 4GoE). In summary, group C mice averaged both significantly higher PSA-specific IgG serum concentrations (31.5-fold; p = 2.5 x 10-6) and percent PSA-specific IgG serum concentrations (9.7-fold; p = 0.0002) than either control group.



View larger version (32K):
[in this window]
[in a new window]
  		FIGURE 4. Ig production in hu-PBL-SCID mice generated from donor 1. The hu-PBL-SCID mice were reconstituted with 1 x 108 donor 1 PBMC and immunized as described in Materials and Methods. Serum was collected on days 14 and 28. Total and PSA-specific human Ig were quantitated by ELISA. A, B, and F–H show results for individual mice. Symbols representing individual mice remain constant for all graphs. C–E show averaged data for group A (closed circles), group B (closed inverted triangle), and group C (open inverted triangle) on days 14 and 28 ± SEM. The relative quantity of PSA-specific IgG was calculated as follows: PSA-specific IgG/total IgG x 100. Student’s paired t test was used to determine the statistical differences between the average IgG serum concentrations of group A or B and the average IgG serum concentrations of group C on day 28 as described in Materials and Methods. p < 0.05 was considered statistically significant. A, PSA-specific IgM serum concentrations (OD490 at 1/10 dilution). B, Total IgM serum concentrations (micrograms per milliliter). The concentration of IgM in group C sera ranged between 35.9–154.6 µg/ml IgM. The concentration of IgM in group A and B sera ranged between 0.6–122.8 µg/ml. There was no significant difference in total or PSA-specific IgM concentrations among the three groups (p > 0.5). C, Average PSA-specific IgG serum concentrations. D, Average IgG serum concentrations. E, Average percent PSA-specific IgG. F, PSA-specific IgG concentrations on day 28. G, Total IgG concentrations on day 28. H, Percent PSA-specific IgG on day 28. The data show that group C mice produced significantly more PSA-specific IgG than group A and B mice.

 
To establish the reproducibility of our hu-PBL-SCID immunization method, additional SCID mice were reconstituted with donor 3 PBMC and immunized by similar methods. Specifically, mice in groups D, E, and F (four mice per group) were engrafted with 1 x 108 PBMC on day 0. Group D mice were immunized with 25 µg of PSA-IgG2a weekly starting on day 0 and with 6.9 x 106 thawed autologous PBMC on day 7. Group E mice were immunized with 25 µg of PSA weekly starting on day 0 and with 6.9 x 106 PSA-pulsed DC cultures on day 7. Group F mice were immunized with 25 µg of PSA-IgG2a weekly starting on day 0 and with 6.8 x 106 PSA-IgG2a-pulsed DC cultures on day 7. DC cultures generated from donor 3 were 70% CD1alow/CD14low/CD32+/CD64low DC. Similar to the results obtained with donor 1 mice, all three groups had similar total and PSA-specific IgM serum concentrations on day 14 (Fig. 5Go, A and B). On day 28 group F mice averaged both significantly higher PSA-specific IgG serum concentrations (3.5-fold; p = 0.04) and percent PSA-specific IgG serum concentrations (2.3-fold; p = 0.04) than either control group (Fig. 5Go, C–H).



View larger version (32K):
[in this window]
[in a new window]
  		FIGURE 5. Ig production in hu-PBL-SCID mice generated from donor 3. The hu-PBL-SCID mice were reconstituted with 1 x 108 donor 2 PBMC and immunized as described in Materials and Methods. Serum was collected on days 14 and 28. Total and PSA-specific human Ig were quantitated by ELISA. A, B, and F–H show results for individual mice. Symbols representing individual mice remain constant for all graphs. C–E show averaged data ± SEM for group D (closed circles), group E (open circles), and group F (inverted triangles) on days 14 and 28. The relative quantity of PSA-specific IgG was calculated as follows: PSA-specific IgG/total IgG x 100. Student’s paired t test was used to determine the statistical differences between the average IgG serum concentrations of group D or E and the average IgG serum concentrations of group F on day 28 as described in Materials and Methods. p > 0.05 was considered statistically significant. A, PSA-specific IgM serum concentrations (OD490 at 1/10 dilution). B, Total IgM serum concentrations (micrograms per milliliter). The concentration of IgM in group F serum ranged between 35.9–154.6 µg/ml IgM. The concentration of IgM in group D and E serum ranged between 0.6–122.8 µg/ml. There was no significant difference in total or PSA-specific IgM concentrations among the three groups (p > 0.5). C, Average PSA-specific IgG serum concentrations. D, Average IgG serum concentrations. E, Average percent PSA-specific IgG. F, PSA-specific IgG concentrations on day 28. G, Total IgG concentrations on day 28. H, Percent PSA-specific IgG on day 28. The data show that group F mice produced significantly more PSA-specific IgG than group D and E mice.

 
When the day 28 data generated from the two random donors are analyzed together, it is clear that immunization with PSA-IgG2a-pulsed DC and PSA-IgG2a produced both the highest and the most consistent PSA-specific IgG responses. Only 3 of 24 control mice (12.5%) produced >5 µg/ml PSA-specific IgG. The best responding control mouse produced 5.7 µg/ml PSA-specific IgG, and that represented only 1.7% of the total response. In addition, only 2 of 24 group A, B, D, and E mice (8%) produced 1.5% or more PSA-specific IgG. In contrast, all 12 group C and F mice (100%) produced >5 µg/ml PSA-specific IgG, and 11 of 12 mice (96%) produced 1.5% or more PSA-specific IgG.

To confirm the reproducibility of this immunization protocol, group G mice were generated from random donor 4 and immunized as described for group F mice, except group G mice were immunized with 3.5 x 106 PSA-IgG2a pulsed DC cultures on day 7. Group G mice were bled on days 14 and 21. Of the three donors tested, donor 4 PBMC produced both the highest PSA-specific IgG serum concentrations and the highest percent PSA-specific IgG serum concentrations. On day 14, PSA-specific IgG concentrations ranged between 1.1–17.8 µg/ml (Fig. 6GoA). PSA-specific IgG serum concentrations increased dramatically in some mice. By day 21, PSA-specific IgG serum concentrations ranged between 4.2–196.5 µg/ml. In addition, group G mice produced between 1.9–59.4% PSA-specific IgG by day 21 (Fig. 6GoB).



View larger version (19K):
[in this window]
[in a new window]
  		FIGURE 6. IgG production in hu-PBL-SCID mice generated from donor 4. The hu-PBL-SCID mice were reconstituted with 1 x 108 donor 4 PBMC and immunized as described in Materials and Methods. Serum was collected on days 14 and 21. Total and PSA-specific human Ig were quantitated by ELISA. The data show results for individual mice. Symbols representing individual mice remain constant for all graphs. The relative quantity of PSA-specific IgG was calculated as follows: PSA-specific IgG/total IgG x 100. A, PSA-specific IgG serum concentrations. B, IgG serum concentrations. C, Percent PSA-specific IgG serum concentrations. The data show that group G mice produced high serum concentrations of PSA-specific IgG.

 
In summary, DC cultures pulsed with PSA-IgG2a consistently stimulated PSA-specific IgG production in hu-PBL-SCID mice generated from all female donors tested. Control mice immunized with PSA-pulsed DC cultures or PSA-IgG2a in combination with an equivalent number of additional autologous PBMC stimulated inconsistent and low level PSA-specific human IgG production.

Analysis of hu-PBL-SCID serum IgG for PSA specificity

To confirm that hu-PBL-SCID serum IgG was specific for PSA, pooled group C serum IgG (92 µg/ml PSA-specific IgG) was compared with mouse A.1 serum IgG (<1 µg/ml PSA-specific IgG) and purified polyclonal control IgG in a PSA-specific ELISA. Group C serum IgG bound PSA 10 times greater than background binding generated by equivalent concentrations of either mouse A.1 serum IgG or control human IgG (Fig. 7GoA). The specificity of group C serum IgG for PSA was further confirmed using soluble PSA as a competitor for group C serum IgG binding to PSA immobilized on a surface. Soluble PSA inhibited group C serum IgG binding in a dose-dependent manner (Fig. 7GoB). Also, 20 µg/ml of soluble PSA reduced pooled group C serum IgG binding to background titers.



View larger version (20K):
[in this window]
[in a new window]
  		FIGURE 7. PSA specificity of group C serum IgG. Equal quantities of sera from four group C mice were pooled (total IgG = 1.7 mg/ml). A, Relative PSA specificity. Human IgG in group C serum binds PSA 10 times better than group A serum at an equivalent concentration of IgG or an equivalent concentration of purified human IgG. B, Soluble PSA competition ELISA. Soluble PSA inhibits the binding of group C serum IgG to immobilized PSA in a concentration-dependent manner.

 
Immunoblot analysis of hu-PBL-SCID sera

Immunoblot analysis of pooled group C sera was performed to determine whether PSA-specific IgG recognized conformational epitopes on PSA. Replica blots were generated from 2.5 µg of PSA following SDS-PAGE under nonreducing conditions, as described in Materials and Methods. Group C serum IgG bound most strongly to a 37-kDa PSA isoform and to a 25-kDa fragment (Fig. 8GoA). Group C serum IgG also bound to the other PSA isoforms and fragments between 12–34 kDa, but with less intensity. No human IgG binding to PSA was observed on blots probed with control IgG (Fig. 8GoB). Group C serum IgG also bound PSA on immunoblots generated from SDS-PAGE under reducing conditions, but with reduced intensity (data not shown). Apparently, Ab generated from donor 1 responded most intensely to an epitope(s) that is associated with secondary structures formed by one of the several cysteine disulfide bonds present in PSA (30).



View larger version (70K):
[in this window]
[in a new window]
  		FIGURE 8. Immunoblot analysis of group C serum IgG. Kaleidoscope prestained standards (lanes 1) and 2.5 µg PSA samples (lanes 2) were boiled in 1x nonreducing Laemmli sample buffer for 5 min and then separated by SDS-PAGE. Size marker molecular mass units are shown as kilodaltons. A, Immunoblot probed with pooled group C serum diluted 1/100 followed by goat anti-human IgG-HRP at 1/20,000. B, Identical immunoblot probed with an equivalent concentration (17 µg/ml) of purified polyclonal human IgG. Pooled group C serum IgG bound to the several PSA isoforms, but most strongly to 37- and 25-kDa isoforms.

 
IgG4 isotype analysis of hu-PBL-SCID sera

IgG4 isotype-specific ELISA were performed on pooled sera from groups A–F to determine whether enhanced Th2 cell activation (e.g., IL-4 production) may have influenced PSA-specific IgG production in group C and F mice (31, 32). On day 25, the concentration of IgG4 in pooled group C serum was 4.5- and 6.5-fold greater than the concentrations of IgG4 in pooled sera from groups A and B, respectively (Fig. 9GoA). Group C mice also produced up to 3-fold more IgG4 relative to total IgG than control mice (Fig. 9BGo). Similarly, the concentration of IgG4 in day 28 pooled group F sera was 3.3- and 2.5-fold greater than the concentrations of IgG4 in pooled sera from groups D and E, respectively (Fig. 9GoC). Group F mice also produced up to 3.1-fold more IgG4 relative to total IgG compared with control mice (Fig. 9GoD). Thus, enhanced PSA-specific IgG production occurred in hu-PBL-SCID mice with enhanced IgG4 production.



View larger version (30K):
[in this window]
[in a new window]
  		FIGURE 9. IgG4 isotype analysis of pooled hu-PBL-SCID sera. IgG4 isotype-specific ELISA was performed on pooled sera from groups A–F as described in Materials and Methods. Sera from donor 1 mice (groups A, B, and C) were collected on day 25. Sera from donor 3 mice (groups D, E, and F) were collected on day 28. Total IgG concentrations in day 25 pooled group A, B, and C sera were 0.43, 0.51, and 1.12 mg/ml, respectively (data not shown). Total IgG concentrations in day 28 pooled group D, E, and F sera were 322, 577, and 463 µg/ml, respectively (Fig. 4Go). Error bars show ±SD for replicate wells. The percent IgG4 concentrations were determined as follows: IgG4/total IgG x 100. A, IgG4 concentration in mouse sera generated from donor 1. B, Ratio of IgG4 to total IgG in mouse serum generated from donor 1. C, IgG4 concentrations in mouse serum generated from donor 3. D, Ratio of IgG4 to total IgG in mouse serum generated from donor 3. The data show that IgG4 concentrations were up to 6.5-fold elevated in sera of mice immunized with PSA-IgG2a-pulsed DC and up to 3.1-fold enhanced relative to IgG concentrations.

 
Phenotype analysis of Ag-stimulated DC

PSA-IgG2a-pulsed DC, PSA-pulsed DC, and mock-treated DC were analyzed by flow cytometry to determine whether altered immunoregulatory surface molecule expression could have contributed to the distinct PSA-specific IgG stimulatory capabilities of PSA-IgG2a-pulsed DC. Briefly, three sets of triplicate cultures were generated from three donors in three separate experiments. One set of triplicate cultures generated from each donor was pulsed with PSA, another set was pulsed with PSA-IgG2a, and the final set was mock treated on day 6. Identical triplicate cultures were pooled and analyzed on day 7. The results showed that MHC class II, CD40, B7.1, and B7.2 surface expression was enhanced on PSA-pulsed DC relative to that on mock-treated DC for all donors tested (Table IGo). When results for the three donors were averaged, MHC class II surface expression was enhanced 2-fold (p = 0.004). In addition, the average surface expression of B7.1, B7.2, and CD40 was enhanced 4.4-fold (p = 0.02), 2.1-fold (p = 0.0004), and 2.7-fold (p = 0.04), respectively. Contrary to expectations, little or no enhancement of B7.1, CD40, and MHC class II surface expression occurred when DC cultures were pulsed with PSA-IgG2a (p >= 0.12). Interestingly, the average B7.2 expression was enhanced 1.4-fold on PSA-IgG2a-pulsed DC compared with B7.2 expression on mock-treated DC (p = 0.02). Thus, PSA-specific IgG production was associated with DC that only had significantly enhanced B7.2 surface expression and not with DC that had significantly enhanced surface expression of B7.1, B7.2, CD40, and MHC class II molecules.


View this table:
[in this window]
[in a new window]
  		Table I. Effects of PSA and PSA-IgG2a on DC immunoregulatory surface molecule expression1

 
Analysis of CD1a and CD14 expression was also included to determine whether PSA-IgG2a- or PSA-pulsed DC developed into the CD1a+/CD14- or CD1a-/CD14+ human DC subtypes characterized by Caux et al. (33). Neither CD1a nor CD14 expression was significantly enhanced on PSA-IgG2a-pulsed or PSA-pulsed DC, but, on the average, PSA-IgG2a-pulsed DC expressed significantly less CD14 (p = 0.03). In summary, the data show that different types of Ag stimulation yielded DC with different phenotypes.


   Discussion
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
References
 
Generation of human mAbs to human TAA is an interest of our laboratory, as such Abs have potential in cancer therapy (34, 35). A major limitation to isolation of high affinity, TAA-specific human mAb is the unavailability of appropriately primed and activated B cells. Because there are reports that describe neo-Ag- and self-Ag-specific human IgG production in SCID mice reconstituted with PBMC from normal donors, we reasoned that high Ag-specific titers could be induced in properly immunized hu-SCID mice (2, 6, 7). As was described for other weakly immunogenic Ag, immunization of hu-PBL-SCID mice with PSA on emulsion-based adjuvant did not stimulate PSA-specific IgG responses (1, 29). However, as we showed here, immunization with PSA-IgG2a-pulsed autologous DC consistently stimulated high titer, PSA-specific human IgG responses in hu-PBL-SCID mice established from all tested donors. These results represent an important first step toward generating human mAb specific for human TAA because we have previously shown that Ag-specific IgG-producing B cells isolated from hu-SCID mice with high Ag-specific IgG titers can be immortalized (2). In addition, we showed that this method generates TAA-specific IgG responses against conformational epitope(s), thus suggesting that some TAA-specific mAb immortalized from hu-PBL-SCID mice will bind to relevant native protein structures.

We suggest that one factor in the successful stimulation of PSA-specific IgG production was the intentional use of female donors. Previous in vitro experiments comparing male and female splenocyte cultures revealed that only female cells were capable of producing PSA-specific IgG (36). We had suggested that this was due to the fact that males are naturally tolerized to PSA, while females are not. In fact, PSA-specific IgG titers have been documented in a few normal females (37). Thus, PSA-specific IgG production by female leukocytes is more akin to a neo-Ag response than to a self-Ag response. It would be interesting to use this model to determine whether tolerance to self-Ag expressed during ontogeny is different from tolerance to self-Ag expressed following puberty.

Previous reports have established that murine IgG2a binds to human Fc{gamma}R via the Fc region of the IgG2a heavy chain (24, 25). We showed here that PSA-IgG2a bound to human DC. Therefore, PSA-specific IgG production by hu-PBL-SCID mice was probably facilitated by targeting PSA to Fc{gamma}R on human DC by the Fc region of PSA-IgG2a. This is supported by the results reported by Ingmar et al., who showed that human Fc{gamma}RI transgenic mice immunized with a human Fc{gamma}RI-specific mAb containing antigenic determinants had greatly enhanced target Ag-specific IgG responses compared with those of littermate controls (38).

It is interesting to consider how targeting PSA to Fc{gamma}R on human DC may have enhanced PSA-specific humoral responses. It is known that complexing Ag to an Ag-specific mAb decreases the quantity of Ag required for human APC to elicit half-maximal proliferation responses from Ag-specific T cells up to 1000-fold (23, 39). It has been suggested that increased immunogenicity is due to efficient Ag capture by Fc{gamma}R and consequential enhanced Ag presentation by MHC molecules (39). It has also been previously established by ourselves and others that Th cell help is required for Ag-specific Ab production in similar hu-SCID models (2, 8, 40). Therefore, PSA-specific IgG production may have been due in part to an increased immunogenicity of PSA, i.e., a greater frequency of PSA-specific Th cell activation. As a result, the minimum amount of PSA-specific Th cell help needed by PSA-specific B cells may have been consistently achieved in mice immunized with PSA-IgG2a-pulsed DC, but not in control mice. However, it is well established that there is sufficient TAA capture and presentation by soluble TAA-pulsed DC to activate T cells and stimulate TAA-specific Th1-type and/or CTL responses (i.e., cellular immunity) in vitro and in vivo (12, 16, 17, 18, 19, 41, 42, 43). Thus, these studies suggest that additional factors other than enhanced PSA presentation may have also contributed to enhanced PSA-specific humoral responses by our PSA-IgG2a-pulsed DC immunized mice.

We showed here that stimulating naive DC cultures with either soluble Ag or Ag-mAb complexes induced DC with significantly distinct phenotypes. B7.1, B7.2, CD40, and MHC class II surface expression was significantly enhanced on soluble PSA-pulsed DC relative to that on mock-treated naive DC. In addition, enhancement of B7.1 and CD40 surface expression was neither a donor-specific nor a PSA-specific occurrence. Similar results were obtained when donor 5 DC were pulsed either with the recall Ag, tetanus toxoid, or with the neo-Ag, horse ferritin (data not shown). Apparently, stimulation by soluble Ag leads to a surface molecule expression pattern that is associated with activation (14, 44, 45). It has recently been shown that human and murine DC express and use mannose/fucose receptors for absorptive endocytosis and presentation of neo-glycoproteins to T cells (46, 47, 48). Perhaps Ag binding to glycosylated protein receptors on DC and/or endocytosis of glycosylated Ag by surface membrane receptors produced activation enhancing signaling events that led to the distinct phenotypic changes we characterized. Regardless, our data raise the possibility that these distinct DC had different effects on Th effector cell maturation, and that the DC phenotype induced by PSA-IgG2a pulsing may have contributed to the enhanced PSA-specific humoral immune responses. This idea is supported by recent reports that show that APC with different immunoregulatory molecule surface expression levels, particularly different B7.1 and B7.2 levels, stimulate distinct Th cell effector functions (28, 49, 50). Analysis of IL-4, IL-2, and INF-{gamma} serum concentrations was considered as a means to determine relative differences in Th1 or Th2 activation, but previous attempts to identify these cytokines in sera generated from similar SCID models were inconclusive (P. Brams, unpublished observations). Rather, we showed here that PSA-IgG2a DC-immunized mice produced up to 3.1-fold more IgG4 relative to total IgG compared with control mice. This observation strongly suggests Th2 activation was enhanced in group C and F mice because IgG4 production is specifically associated with B cell stimulation by the Th2-derived cytokine, IL-4 (31, 32, 51). Unfortunately, we could not detect any PSA-specific IgG4 (data not shown). This result was not unexpected, since the sensitivity of our isotype-specific assays is greatly reduced compared with polyclonal targeting of both IgG heavy and light chains. Regardless, when DC phenotype and relative IgG4 expression data are evaluated together, it suggests a model with greatly enhanced B7.1 costimulation by PSA-pulsed, DC-polarized, PSA-specific Th cells to a Th1 phenotype through DC/T cell feedback maturation and differentiation (28, 52, 53, 54, 55). Without sufficient additional Th2 activation, little or no PSA-specific IgG1 was produced by group B and E mice (51). In contrast, PSA-IgG2a-pulsed DC only had significantly enhanced B7.2 surface expression compared with naive DC. This suggests the inverse of the same model, where significantly more B7.2 may have mediated PSA-specific IgG1 production by directing more frequent Th2 activation than in control mice (28, 49). Increased Th2 activation may have subsequently stimulated enhanced PSA-specific IgG1 production by direct Th2 cytokine stimulation of B cells and through Th2 cytokine-modified Th1 help (51, 56, 57, 58, 59, 60). We plan to investigate whether Th1/Th2 deviation can be influenced by an Ag-Ab complex pulsed vs Ag-pulsed DC in vitro, where both cytokine production and costimulatory surface molecule expression by the responding T cells can be fully analyzed.

In summary, our results showed that DC pulsed with Fc{gamma}R-binding PSA-mAb complexes consistently and reproducibly stimulated PSA-specific IgG responses in hu-PBL-SCID mice, but DC pulsed with PSA did not. Interestingly, functional IgG responses were associated with immunizing DC that had enhanced B7.2 surface expression but with B7.1, MHC class II, and CD40 surface expression levels comparable to those of naive DC. Furthermore, as we previously shown that Ag-specific IgG responses can be immortalized from hu-SCID mice with Ag-specific IgG titers, our results open the possibility that this immunization strategy may be useful for generating human mAb to human TAA and other weakly immunogenic Ag (2).


   Acknowledgments
 
We thank the San Diego Blood Bank for providing donors and leukopheresed PBMC. We also thank William Carlisle for his help with this work, and Dr. Mitchell Reff for his assistance in preparing this manuscript.


   Footnotes
 
1 This work was supported in part by National Institutes of Health Grant 5R29CA64034. Back

2 Address correspondence and reprint requests to Dr. M. A. Coccia, IDEC Pharmaceuticals, Inc., 11011 Torreyana Rd., San Diego, CA 92121. Back

3 Abbreviations used in this paper: hu, human; SPL, spleen cells; TAA, tumor-associated Ag; DC, dendritic cell(s); GM-CSF, granulocyte-macrophage CSF; PSA, prostate specific Ag; IN2, Iscove’s complete medium and 2% Nutridoma HU; PE, phycoerythrin; MFI, mean fluorescence intensity; HRP, horseradish peroxidase; OPD, o-phenylenediamine dihydrochloride; PBST, PBS and 0.05% Tween; GS-PBST, 5% goat serum and PBST. Back

Received for publication April 7, 1998. Accepted for publication July 14, 1998.


   References
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 

  1. Bosma, M. J., A. M. Carroll. 1991. The scid mouse mutant: definition, characterization and potential uses. Annu. Rev. Immunol. 9:323.[Medline]
  2. Brams, P., M.-L. Nguyen, S. Chamat, I. Royston, P. R. Morrow. 1998. Antigen-specific IgG responses from naive human splenocytes: in vitro priming followed by antigen boost in the SCID mouse. J. Immunol. 160:2051.[Abstract/Free Full Text]
  3. Coccia, M. A., S. Weeks, K. Knott, K. Kuus-Reichel. 1998. Endogenous IL-6 enhances lymphocyte engraftment but not antibody production in SCIDhu PBL mice. Immunobiology 198:396.[Medline]
  4. Walker, W., G. Gallagher. 1994. The in vivo production of specific human antibodies by vaccination of human-PBL-SCID mice. Immunology 83:163.[Medline]
  5. Mosier, D. E.. 1991. Adoptive transfer of human lymphoid cells to severely immunodeficient mice, models for normal human immune function, autoimmunity, lymphomagenesis and AIDS. Adv. Immunol. 50:303.[Medline]
  6. Ifversen, P., C. Martensson, L. Danielsson, C. Ingvar, R. Carlsson, C. A. K. Borrebaek. 1995. Induction of primary antigen-specific immune responses in SCID-hu-PBL mice by coupled T-B epitopes. Immunology 84:111.[Medline]
  7. Uchibayashi, N., R. Sasada, A. Shino, M. Okada, Y. Ohkubo, T. Ochi, O. Shiho. 1995. A human monoclonal antibody to human self-antigen, CD2, derived from human peripheral blood lymphocytes engrafted in SCID mice. Hybridoma 14:313.[Medline]
  8. Williams, S. S., F.-A. Chen, H. Kida, S. Yokota, K. Miya, M. Kato, M. Barcos, H. Wang, T. Alosco, T. Umemoto, et al 1996. Engraftment of human tumor-infiltrating lymphocytes and production of anti-tumor antibodies in SCID mice. J. Immunol. 156:1908.[Abstract]
  9. Cella, M., F. Sallusto, A. Lanzavecchia. 1997. Origin, maturation and antigen presenting function of dendritic cells. Curr. Opin. Immunol. 9:10.[Medline]
  10. Peters, J. H., R. Gieseler, B. Theile, F. Steinbach. 1996. Dendritic cells: from ontogenic orphans to myelomonocytic descendants. Immunol. Today 17:273.[Medline]
  11. Romani, N., S. Gruner, D. Brang, E. Kampgen, A. Lenz, B. Trockenbacher, G. Konwalinka, P. O. Fritsch, R. M. Steinman, G. Schuler. 1994. Proliferating dendritic cell precursors in human blood. J. Exp. Med. 180:83.[Abstract/Free Full Text]
  12. Caux, C., C. Massacrier, C. Dezutter-Dambuyant, B. Vanbervliet, C. Jacquet, D. Schmitt, J. Banchereau. 1995. Human dendritic Langerhans cells generated in vitro from CD34+ progenitors can prime naive CD4+ T cells and process soluble antigen. J. Immunol. 155:5427.[Abstract]
  13. Santiago-Schwartz, F., K. Laky, S. E. Carson. 1995. Stem cell factor enhances dendritic cell development. Adv. Exp. Med. Biol. 378:7.[Medline]
  14. Linsley, P. S., W. Brady, L. Grosmaire, A. Aruffo, N. K. Damle, J. A. Ledbetter. 1991. Binding of the B cell activation antigen B7.1 to CD28 costimulates T cell proliferation and interleukin 2 mRNA accumulation. J. Exp. Med. 173:721.[Abstract/Free Full Text]
  15. Caux, C., B. Vanbervleit, C. Massacrier, M. Azuma, K. Okumura, L. Lanier, J. Banchereau. 1994. B70/B7.2 is identical to CD86 and is the major functional ligand for CD28 expressed on human dendritic cells. J. Exp. Med. 180:1841.[Abstract/Free Full Text]
  16. Bakker, A. B. H., G. Marland, A. J. de Boer, R. J. F. Huijbens, E. H. J. Danen, G. J. Adema, C. G. Figdor. 1995. Generation of cytotoxic T lymphocytes from healthy donors after presentation of melanoma-associated antigen derived epitopes by dendritic cells in vitro. Cancer Res. 55:5330.[Abstract/Free Full Text]
  17. Van Elsas, A., S. H. Van der Burg, C. E. Van der Minne, M. Borhi, J. S. Mourer, C. J. M. Melief, P. I. Schrier. 1996. Peptide pulsed dendritic cells induce tumoricidal cytotoxic T lymphocytes from healthy donors against stable HLA-A*0201-binding peptides from the Melan-A/MART-1 self antigen. Eur. J. Immunol. 26:1683.[Medline]
  18. Tjoa, B., A. Boynton, G. Kenny, H. Ragde, S.L. Misrock, G. Murphy. 1996. Presentation of prostate tumor antigens by dendritic cells stimulates T-cell proliferation and cytotoxicity. Prostate 28:65.[Medline]
  19. Tjoa, B. A., S. J. Erickson, V. A. Bowes, H. Ragde, G. M. Kenny, O. E. Cobb, R. C. Ireton, M. J. Troychak, A. L. Boyton, G. P. Murphy. 1997. Follow up evaluation of prostate cancer patients infused with autologous dendritic cells pulsed with PMSA peptides. Prostate 32:277.
  20. Fanger, N. A., K. Wardell, L. Shen, T. Tedder, P. M. Guyre. 1996. Type I (CD64) and type II (CD32) Fc{gamma}R receptor-mediated phagocytosis by human blood dendritic cells. J. Immunol. 157:541.[Abstract]
  21. Fanger, N., D. Voigtlaender, C. Liu, S. Swink, K. Wardwell, J. Fisher, R. F. Graziano, C. Pfefferkorn, P. M. Guyre. 1997. Characterization of expression, cytokine regulation and effector function of the high affinity receptor Fc{gamma}RI (CD64) expressed on human blood dendritic cells. J. Immunol. 158:3090.[Abstract]
  22. Gosselin, E. J., K. Wardell, D. R. Gosselin, N. Alter, J. L. Fischer, P. M. Guyre. 1992. Enhanced antigen presentation using Fc{gamma} receptor (monocyte-macrophage)-specific immunogens. J. Immunol. 149:3477.[Abstract]
  23. Sallutso, F., A. Lanzavecchia. 1994. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and down-regulated by tumor necrosis factor {alpha}. J. Exp. Med. 179:1109.[Abstract/Free Full Text]
  24. Simmons, D., B. Seed. 1988. The Fc{gamma} receptor of natural killer cells is a phospholipid-linked membrane protein. Nature 333:568.[Medline]
  25. Jones, D. H., R. J. Looney, C. L. Anderson. 1985. Fc{gamma} receptors on a human monocyte line (U937) defined by differences in binding of murine IgG subclasses at low ionic strength. J. Immunol. 135:3348.[Abstract]
  26. Mossman, T. R., R. L. Coffman. 1989. Th1 and Th2 cells: different patterns of lymphokine secretion lead to different functional properties. Annu. Rev. Immunol. 7:793.
  27. Powrie, F., R. L. Coffman. 1993. Cytokine regulation of T-cell function: a potential for therapeutic intervention. Immunol. Today 14:270.[Medline]
  28. Kuchroo, V. K., M. P. Das, J. A. Brown, A. M. Ranger, S. S. Zamvil, R. A. Sobel, H. L. Weiner, N. Nabavi, L. H. Glimcher. 1995. B7.1 and B7.2 costimulatory molecules activate differentially the Th1/Th2 developmental pathways: application to autoimmune disease therapy. Cell 80:707.[Medline]
  29. Bankert, R. B., T. Umemoto, Y. Sugiyama, F. A. Chen, E. Repasky, S. Yokota. 1989. Human lung tumors, patients’ peripheral blood and tumor infiltrating lymphocytes propagated in scid mice. Curr. Top. Microbiol. Immunol. 152:201.[Medline]
  30. Watt, K. W. K., P. J. Lee, T. M’Timkulu, W. P. Chan, R. Loor. 1986. Human prostate-specific antigen: structural and functional similarity with serine proteases. Proc. Natl. Acad. Sci. USA 83:3166.[Abstract/Free Full Text]
  31. Stevens, T. L., A. Bossie, V. M. Sanders, R. Fernandez-Bortran, R. L. Coffman, T. R. Mossman, E. S. Vitetta. 1988. Regulation of antibody isotype secretion by subsets of antigen-specific helper T cells. Nature 334:255.[Medline]
  32. Lundgren, M., U. Perrson, P. Larrson, C. Magnusson, C. I. E. Smith, L. Hammarstrom, E. Severison. 1989. Interleukin-4 induces synthesis of IgE and IgG4 in human B cells. Eur. J. Immunol. 19:1311.[Medline]
  33. Caux, C., B. Vanbervliet, C. Massacrier, C. Dezutter-Dambuyant, B. de Saint-Vis, C. Jacquet, K. Yoneda, S. Imamura, D. Schmitt, J. Banchereau. 1994. CD34+ hematopoietic progenitors from human cord blood differentiate along two independent dendritic cell pathways in response to GM-CSF + TNF{alpha}. J. Exp. Med. 184:695.[Abstract/Free Full Text]
  34. Ritz, J., J. M. Pesando, S. E. Sallan, L. A. Clavell, J. Notis-McConarty, P. Rosenthal, S. F. Schlossman. 1981. Serotherapy of acute lymphoblastic leukemia with monoclonal antibody. Blood 44:5914.
  35. Maloney, D. G., T. M. Liles, D. K. Czerwinski, C. Waldichuck, J. Rosenberg, A. Grillo-Lopez, R. Levy. 1994. Phase I clinical trial using escalating dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma. Blood 84:2457.[Abstract/Free Full Text]
  36. Lu, E. W., A. T. Bustaria, I. Royston, P. Brams. 1993. Factors affecting production of antibodies to prostate antigens by in vitro-primed human splenocytes. Hybridoma 12:381.[Medline]
  37. Oesterling, J. E.. 1991. Prostate specific antigen: a valuable clinical tool. Oncology 5:107.
  38. Ingmar, A., F. M. Heijnen, M. J. van Gugt, N. A. Fanger, R. F. Graziano T. P. M. de Wit, F. M. A. Hofhuis, P. M. Guyre, P. J. A. Capel, J. S. Verbeek, et al 1996. Antigen targeting to myeloid-specific human Fc{gamma}RI/CD64 triggers enhanced antibody responses in transgenic mice. J. Clin. Invest. 97:331.[Medline]
  39. Liu, C., J. Goldstein, R. F. Graziano, H. Jai, J. K. O’Shea, Y. Deo, P. M. Guyre. 1996. Fc{gamma}RI-targeted fusion proteins result in efficient presentation by human monocytes of antigenic and antagonistic T cell epitopes. J. Clin. Invest. 98:2001.[Medline]
  40. Chen, F.-A., S. S. Williams, W. C. Fanslow, R. B. Bankert. 1995. Human antibody response in human peripheral blood leukocyte/severe combined immunodeficient chimeric model is dependent on B and T cell costimulation via CD40/CD40 ligand. J. Immunol. 155:2833.[Abstract]
  41. Porgador, A., D. Snyder, E. Gilboa. 1996. Induction of anti-tumor immunity using bone marrow-generated dendritic cells. J. Immunol. 156:29.-18.
  42. Zitvogel, L., J. I. Mayordomo, T. Tjandrawan, A. B. DeLeo, M. R. Clarke, M. T. Lotze, W. J. Storkus. 1996. Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines J. Exp. Med. 183:87.
  43. Celluzi, C. M., J. I. Mayordomo, M. T. Lotze, L. D. Falo. 1996. Peptide-pulsed dendritic cells induce antigen-specific, CTL-mediated protective immunity. J. Exp. Med. 183:283.[Abstract/Free Full Text]
  44. Boussiotis, V. A., G. J. Freeman, J. G. Gribben, J. Daley, G. Gray, L. M. Nadler. 1993. Activated human B lymphocytes express three CTLA-4 counterreceptors that stimulate T-cell activation. Proc. Natl. Acad. Sci. USA 90:11059.[Abstract/Free Full Text]
  45. Hart, D. N., G. C. Starling, V. L. Calder, N. S. Fernando. 1993. B7/BB-1 is a leukocyte differentiation antigen on human dendritic cells induced by activation. Immunology 4:616.
  46. Avraméas, A., D. McIlroy, A. Hosmalin, B. Autran, P. Debré, M. Monsigny, A. C. Roche, P. Midoux. 1996. Expression of a mannose/fucose membrane lectin on human dendritic cells. Eur. J. Immunol. 26:394.[Medline]
  47. Jiang, W., W. J. Swiggard, C. Heufler, M. Peng, A. Mirza, R. M. Steinman, N. C. Neussenzweig. 1995. The receptor DEC-205 expressed by dendritic cells and thymic epithelial cells is involved in antigen processing. Nature 375:151.[Medline]
  48. Lu, J.. 1997. Collectins: collectors of microorganisms for the innate immune system. Bioessays 19:509.[Medline]
  49. Freeman, G. J., V. A. Boussiotis, A. Anumanthan, G. M. Bernstein, X.-Y. Ke, P. D. Rennert, G. S. Gray, J. G. Gribben, L. M. Nadler. 1995. B7-1 and B7-2 do not deliver identical costimulatory signals, since B7-2 but not B7-1 preferentially costimulates the initial production of IL-4. Immunity 2:523.[Medline]
  50. DiMolfetto, L., H. A. Neal, A. Wu, C. Reilly, D. Lo. 1998. The density of class II MHC T cell receptor ligand influences INF-{gamma}/IL-4 ratios in immune responses in vivo. Cell. Immunol. 183:70.[Medline]
  51. Mossmann, T. R., R. L. Coffman. 1989. Heterogeneity of cytokine secretion patterns and functions of helper T cells. Adv. Immunol. 46:111.[Medline]
  52. Kitajima, T., G. Caceres-Dittmar, F. J. Tapia, J. Jester, P. R. Bergstresser, A. Takashima. 1996. T cell-mediated terminal maturation of dendritic cells. J. Immunol. 157:2340.[Abstract]
  53. Macatonia, S. E., N. A. Hosken, M. Litton, P. Viera, C. S. Hsieh, J. A. Culpepper, M. Wysocka, G. Trinchieri, K. M. Murphy, A. O’Garra. 1995. Dendritic cells produce IL-12 and direct the development of Th1 cells from naive CD4+ cells. J. Immunol. 154:5071.[Abstract]
  54. Cella, M., D. Scheidegger, K. Palmer-Lehmann, P. Lane, A. Lanzavecchia, G. Alber. 1996. Ligation of CD40 on dendritic cells triggers production of high levels of interleukin-12 and enhances T cell stimulatory capacity: T-T help via APC activation. J. Exp. Med. 186:747.
  55. Heufler, C., F. Koch, U. Stanzel, G. Topar, M. Wysocka, G. Trinchieri, A. Enk, R. M. Steinman, N. Romani, G. Schuler. 1996. Interleukin-12 is produced by dendritic cells and mediates T helper 1 development as well as interferon-{gamma} production by T helper 1 cells. Eur. J. Immunol. 26:659.[Medline]
  56. Hino, A., H. Nariuchi. 1996. Negative feedback mechanism suppresses interleukin-12 production by antigen presenting cells interacting with T helper 2 cells. Eur. J. Immunol. 26:623.[Medline]
  57. Ludewig, B., D. Graf, H. R. Gelderblom, Y. Becker, R. A. Kroczek, G. Pauli. 1995. Spontaneous apoptosis of dendritic cells is efficiently inhibited by TRAP (CD40-ligand) and TNF-{alpha}, but strongly enhanced by interleukin-10. Eur. J. Immunol. 25:1943.[Medline]
  58. Koch, F., U. Stanzl, P. Jennewein, K. Janke, C. Heufler, E. Kämpgen, N. Romani, G. Schuler. 1996. High level IL-12 production by murine dendritic cells: upregulation by MHC class II and CD40 molecules and downregulation by IL-4 and IL-10. J. Exp. Med. 184:741.[Abstract/Free Full Text]
  59. Ozawa, H., S. Aiba, S. Nakagawa, H. Tagami. 1996. Interferon-{gamma} and interleukin-10 inhibit antigen presentation by Langerhans cells for T helper type 1 cells by suppressing their CD80 (B7.1) expression. Eur. J. Immunol. 26:648.[Medline]
  60. Itoh, K., S. Hirohata. 1995. The role of IL-10 in human B cell activation, proliferation, and differentiation. J. Immunol. 154:4341.[Abstract]



This article has been cited by other articles:


Home page
 BloodHome page
A. K. Palucka, J. Gatlin, J. P. Blanck, M. W. Melkus, S. Clayton, H. Ueno, E. T. Kraus, P. Cravens, L. Bennett, A. Padgett-Thomas, et al.
Human dendritic cell subsets in NOD/SCID mice engrafted with CD34+ hematopoietic progenitors
Blood, November 1, 2003; 102(9): 3302 - 3310.
[Abstract] [Full Text] [PDF]

Home page
 Int ImmunolHome page
S. K. Yoshinaga, M. Zhang, J. Pistillo, T. Horan, S. D. Khare, K. Miner, M. Sonnenberg, T. Boone, D. Brankow, T. Dai, et al.
Characterization of a new human B7-related protein: B7RP-1 is the ligand to the co-stimulatory protein ICOS
Int. Immunol., October 1, 2000; 12(10): 1439 - 1447.
[Abstract] [Full Text] [PDF]

Home page
 JEMHome page
S. M. Santini, C. Lapenta, M. Logozzi, S. Parlato, M. Spada, T. Di Pucchio, and F. Belardelli
Type I Interferon as a Powerful Adjuvant for Monocyte-derived Dendritic Cell Development and Activity In Vitro and in Hu-PBL-SCID Mice
J. Exp. Med., May 15, 2000; 191(10): 1777 - 1788.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Coccia, M. A.
Right arrow Articles by Brams, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Coccia, M. A.
Right arrow Articles by Brams, P.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS